REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Science & Research
14

Scientific Literature Review: SS-31

Maple Hampton·about 1 month ago
Compiling a literature review on SS-31 for community reference. I have gone through PubMed and pulled the most relevant publications. Total published studies referencing SS-31: dozens, ranging from basic science to clinical trials. The quality varies considerably, with some well-designed RCTs and many smaller observational studies and case reports. Mechanism studies: the receptor pharmacology of SS-31 is well-characterized. Multiple groups have independently confirmed the binding profile and downstream signaling pathways. This is actually a strength of the evidence base — independent replication increases confidence. Efficacy studies: the clinical trial data shows consistent moderate effects on primary endpoints related to recovery, tissue repair, and relevant biomarkers. Effect sizes in the range of 15-30 percent improvement over placebo are typical, which is clinically meaningful. Safety studies: SS-31 has a clean safety record in published literature. The incidence of adverse events is low and severity is mild. No dose-limiting toxicities have been identified within the studied dose ranges. Gaps in the literature: we need more long-duration studies, more diverse study populations, and more head-to-head comparisons with alternative approaches. The existing data is encouraging but incomplete. I maintain a running list of key papers and will share it in the comments for anyone who wants to do their own reading.

Comments (5)

Nico FlynnDEMO·about 1 month ago

I ran SS-31 at a slightly higher dose than what you used and found the results were actually about the same. This lines up with the dose-response data suggesting there is a ceiling effect. Higher dose just meant more injection site irritation without additional benefit. Your approach seems well-calibrated.

5
Wynn DouglasDEMO·about 1 month ago

The sleep improvement you mention with SS-31 has been the most universally reported benefit I see across different users. It seems like regardless of primary goals, almost everyone reports better sleep quality. I wonder if this is a direct effect or downstream from other physiological changes.

6
Payton ForrestDEMO·about 1 month ago

Thanks for the detailed protocol breakdown. I am starting SS-31 next week and this is exactly the kind of practical information I was looking for. The reconstitution tips especially — I have seen conflicting advice elsewhere about water temperature and injection speed. Your approach sounds well-reasoned.

7
Darcy HuntDEMO·about 1 month ago

Been following this thread with interest. My SS-31 experience was similar in most ways, though I found the recovery benefits took a bit longer to kick in for me — closer to week 5-6 rather than 3-4. Individual variation is real and I think people need to be patient before concluding something is or is not working.

2
Cameron LangfordDEMO·about 1 month ago

Solid protocol. One suggestion: consider adding HRV tracking if you are not already. It has been the most objective and responsive metric for me during my SS-31 protocol. Changes in HRV preceded subjective improvements by about a week, which gave me early confidence the protocol was working.

3

Sign in to comment.